Urology Department, Faculty of Medicine, October 6 University, Cairo, Egypt.
Clinical Pathology Department, National Research Center, Cairo, Egypt.
Urol Int. 2022;106(3):291-297. doi: 10.1159/000520597. Epub 2021 Dec 16.
This study aimed to evaluate the effect of bladder wall thickness (BWT) (using transabdominal ultrasound) on the outcomes of antimuscarinic treatment in women with overactive bladder.
A total of 102 female patients with symptoms of OAB were recruited. All patients completed the Overactive Bladder version 8 (OAB-V8) (Arabic validation) and the International Consultation of Incontinence Questionnaire (ICIQ-SF). Patients completed the urodynamic study (UDS) including uroflowmetry and PVR and measures of BWT by transabdominal ultrasound. The patients were classified into 2 major groups: G1 (patients with BWT <5 mm) and G2 (patients with BWT ≥5 mm). The patients were re-evaluated after 3-month medication with solifenacin 10-mg oral tablet.
At baseline, the results of OAB-V8 and ICIQ-SF were significantly higher in G2 than G1 (p < 0.001). Regarding UDS, volume at 1st desire to void, volume at strong desire to void, and MBC were significantly higher in group 1 compared to group 2 (p = 0.001). Intravesical pressure at strong desire and patients' number of DO were significantly increased in G2 (p < 0.05 and p = 0.001, respectively). After treatment, there was an improvement in both groups regarding OAB-V8, ICIQ-SF, bladder volume at 1st desire to void, bladder volume at strong desire to void, bladder volume at DO, MBC, intravesical pressure at strong desire, and the patients' number with DO (decreased), and these improvements were statistically significant in group 1 compared to group 2 (p < 0.05).
BWT showed a significant association with both OAB symptom scores and UDS parameters. The decrease in BWT is associated with a significantly higher response to solifenacin therapy regarding the UDS results.
本研究旨在评估膀胱壁厚度（BWT）（经腹超声）对女性膀胱过度活动症（OAB）患者接受抗毒蕈碱治疗效果的影响。
共招募了 102 名有 OAB 症状的女性患者。所有患者均完成了过动性膀胱量表 8 版（OAB-V8）（阿拉伯语验证）和国际尿失禁咨询问卷简表（ICIQ-SF）。患者完成了尿动力学研究（UDS），包括尿流率和 PVR 以及经腹超声测量 BWT。患者分为 2 个主要组：G1（BWT<5mm）组和 G2（BWT≥5mm）组。患者在口服索利那新 10mg 片剂治疗 3 个月后进行重新评估。
在基线时，G2 组的 OAB-V8 和 ICIQ-SF 评分明显高于 G1 组（p<0.001）。在 UDS 方面，G1 组的首次排尿意愿量、强烈排尿意愿量和最大膀胱容量显著高于 G2 组（p=0.001）。G2 组的膀胱内压在强烈排尿意愿时显著升高，且患者的 DO 次数增加（p<0.05 和 p=0.001）。治疗后，两组患者的 OAB-V8、ICIQ-SF、首次排尿意愿量、强烈排尿意愿量、DO 时的膀胱容量、最大膀胱容量、强烈排尿意愿时的膀胱内压和 DO 次数（减少）均有所改善，且 G1 组的改善情况显著优于 G2 组（p<0.05）。
BWT 与 OAB 症状评分和 UDS 参数均有显著相关性。BWT 下降与索利那新治疗 UDS 结果的反应显著相关。
